The first gene therapy product,recombinant adenovirus human p53(rAd-p53),has been approved by CFDA since 2013.During these years,most of the clinical trials and the relevant basic research were carried out by Chinese ...The first gene therapy product,recombinant adenovirus human p53(rAd-p53),has been approved by CFDA since 2013.During these years,most of the clinical trials and the relevant basic research were carried out by Chinese oncologists.Gendicine was proved to be a safe and promising gene therapy drug for patients who suffered from head and neck squamous cell carcinoma(HNSCC).The basic therapeutic theories of gene therapy were totally different from the traditional ones,such as surgeries or radioand chemotherapy,and the evaluation of treatment outcomes should also be changed simultaneously.However,there still existed a lot of misunderstandings about gene therapy,which resulted in improper administration,insufficient dosage calculation,and treatment cycles,and the treatment outcomes were unsatisfactory,especially for inexperienced oncologists or hospitals.Therefore,we will provide some practical guidance here on the gene therapy of rAd-p53 based on our previous research and experience,which focused on the basic theories and clinical issues,to answer the questions arising during the clinical of gene therapy and to accelerate the development of gene therapy for the benefit of patients bearing malignant tumors.展开更多
Most of the patients with oral and maxillofacial malignancy are in the middle and advanced stages at diagnosis and the incidence rate is increasing in recent years.Chemotherapy alone is difficult to benefit the surviv...Most of the patients with oral and maxillofacial malignancy are in the middle and advanced stages at diagnosis and the incidence rate is increasing in recent years.Chemotherapy alone is difficult to benefit the survival of patients with advanced oral and maxillofacial malignancy.Ultrasound hyperthermia is a new and effective treatment for malignant tumor,which is developing rapidly in addition to conventional treatment.However,at present,ultrasound hyperthermia has not been widely used in the treatment of oral and maxillofacial malignancy.Therefore,formation of a guideline on ultrasound hyperthermia for oral and maxillofacial malignancy is mandatory,in order to promote and standardize the clinical practice of ultrasound hyperthermia in this field,and improve the long-term survival rate and quality of life of patients.展开更多
基金The study was supported by National Natural Science Foundation of China(Grant numbers 81972538 and 81972546).
文摘The first gene therapy product,recombinant adenovirus human p53(rAd-p53),has been approved by CFDA since 2013.During these years,most of the clinical trials and the relevant basic research were carried out by Chinese oncologists.Gendicine was proved to be a safe and promising gene therapy drug for patients who suffered from head and neck squamous cell carcinoma(HNSCC).The basic therapeutic theories of gene therapy were totally different from the traditional ones,such as surgeries or radioand chemotherapy,and the evaluation of treatment outcomes should also be changed simultaneously.However,there still existed a lot of misunderstandings about gene therapy,which resulted in improper administration,insufficient dosage calculation,and treatment cycles,and the treatment outcomes were unsatisfactory,especially for inexperienced oncologists or hospitals.Therefore,we will provide some practical guidance here on the gene therapy of rAd-p53 based on our previous research and experience,which focused on the basic theories and clinical issues,to answer the questions arising during the clinical of gene therapy and to accelerate the development of gene therapy for the benefit of patients bearing malignant tumors.
文摘Most of the patients with oral and maxillofacial malignancy are in the middle and advanced stages at diagnosis and the incidence rate is increasing in recent years.Chemotherapy alone is difficult to benefit the survival of patients with advanced oral and maxillofacial malignancy.Ultrasound hyperthermia is a new and effective treatment for malignant tumor,which is developing rapidly in addition to conventional treatment.However,at present,ultrasound hyperthermia has not been widely used in the treatment of oral and maxillofacial malignancy.Therefore,formation of a guideline on ultrasound hyperthermia for oral and maxillofacial malignancy is mandatory,in order to promote and standardize the clinical practice of ultrasound hyperthermia in this field,and improve the long-term survival rate and quality of life of patients.
